Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: A prospective study in Queensland, Australia

被引:100
作者
Carroll, RP
Ramsay, HM
Fryer, AA
Hawley, CM
Nicol, DL
Harden, PN
机构
[1] Keele Univ, N Staffordshire Hosp, Postgrad Med Sch, Dept Renal Med, Stoke On Trent, Staffs, England
[2] Keele Univ, N Staffordshire Hosp, Postgrad Med Sch, Dept Dermatol, Stoke On Trent, Staffs, England
[3] Keele Univ, N Staffordshire Hosp, Postgrad Med Sch, Clin Biochem Res Grp, Stoke On Trent, Staffs, England
[4] Princess Alexandra Hosp, Renal Transplant Unit, Brisbane, Qld 4102, Australia
关键词
Australia; immunosuppression; incidence; kidney transplantation; nonmelanoma skin cancer (NMSC); predictive index;
D O I
10.1053/ajkd.2003.50130
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Nonmelanoma skin cancer (NMSC) is a significant clinical problem after renal transplantation, particularly in areas of high UV light exposure. A single-center prospective study of a population of Queensland renal transplant recipients was performed with the alms of: (1) establishing NMSC incidence and tumor accrual post-renal transplantation, and (2) developing a clinically derived predictive index to identify transplant recipients at greatest risk. Methods: Three hundred ten of 398 transplant recipients (78%) who underwent baseline assessment between July 1999 and April 2000 were reassessed a mean of 18 +/- 3.5 (SD) months later. A structured interview, full skin examination, biopsy of suspicious lesions, and review of medical and pathological records were used to determine the number and types of NMSC arising between the two assessments. Incidence (percentage of the population developing NMSC per year) and tumor accrual (number of tumors per person per year) were calculated. A clinically derived predictive index was generated using stepwise logistic regression models. Results: Overall NMSC incidence was 28.1% and increased with duration of immunosuppression therapy: 18.8%, 24.8%, 33.3%, and 47.1% at less than 5, 5 to 10, 10 to 20, and greater than 20 years of immunosuppression therapy, respectively. Mean NMSC accrual was 1.85 +/- 3.84 tumors/person/y, increasing to 3.35 +/- 4.29 tumors/person/y after 20 years of immunosuppression therapy. Renal transplant recipients were stratified into categories of high and low NMSC risk by using predictive indices. Conclusion: Clinically derived predictive indices can allow NMSC risk stratification of an Australian transplant population and may provide an evidence-based and cost-effective approach to developing a targeted clinical NMSC surveillance program.
引用
收藏
页码:676 / 683
页数:8
相关论文
共 17 条
[1]   SKIN-CANCER [J].
ARMSTRONG, BK ;
KRICKER, A .
DERMATOLOGIC CLINICS, 1995, 13 (03) :583-594
[2]  
*AUSTR I HLTH WELF, 1998, AUSTR HLTH 1998 6 BI, P86
[3]   The risk of skin cancer in renal transplant recipients in Queensland, Australia [J].
Bavinck, JNB ;
Hardie, DR ;
Green, A ;
Cutmore, S ;
MacNaught, A ;
OSullivan, B ;
Siskind, V ;
VanDerWoude, FJ ;
Hardie, IR .
TRANSPLANTATION, 1996, 61 (05) :715-721
[4]  
EUVRARD S, 1995, TRANSPLANT P, V27, P1767
[5]   NONMELANOMA SKIN-CANCER IN RENAL-TRANSPLANT RECIPIENTS - THE EXTENT OF THE PROBLEM AND A STRATEGY FOR MANAGEMENT [J].
GLOVER, MT ;
NIRANJAN, N ;
KWAN, JTC ;
LEIGH, IM .
BRITISH JOURNAL OF PLASTIC SURGERY, 1994, 47 (02) :86-89
[6]  
GODOWIN RG, 2001, BR J DERMATOL S59, V145, pS17
[7]   Annual incidence and predicted risk of nonmelanoma skin cancer in renal transplant recipients [J].
Harden, PN ;
Fryer, AA ;
Reece, S ;
Smith, AG ;
Ramsay, HM .
TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) :1302-1304
[8]   Skin cancer surveillance in renal transplant recipients: questionnaire survey of current UK practice [J].
Harden, PN ;
Reece, SM ;
Fryer, AA ;
Smith, AG ;
Ramsay, HM .
BRITISH MEDICAL JOURNAL, 2001, 323 (7313) :600-601
[9]  
HARDIE IR, 1995, TRANSPLANT REV, V9, P1
[10]  
Kasiske BL, 2000, J AM SOC NEPHROL, V11, pS1